Performance of the Meta-Analysis Global Group in Chronic Heart Failure Score in Black Patients Compared With Whites

Ryhm Radjef1, Edward L Peterson2, Alexander Michaels1

  • 1Heart and Vascular Institute (R.R., A.M., H.N.S., D.E.L.), Department of Internal Medicine, Henry Ford Hospital, Detroit, MI.

Insights

The MAGGIC score effectively predicts heart failure mortality in Black patients, similar to White patients. This validated tool can be used for risk stratification across racial groups in heart failure care.

Area of Science:

  • Cardiology
  • Health Services Research

Background:

  • Risk stratification is crucial in heart failure (HF).
  • The Meta-Analysis Global Group in Chronic HF (MAGGIC) score is a validated tool for HF risk stratification.
  • Concerns exist about the MAGGIC score's performance in Black patients due to underrepresentation in the original study cohort.

Purpose of the Study:

  • To evaluate the performance of the MAGGIC score in a racially diverse cohort of heart failure patients.
  • To assess the discrimination and calibration of the MAGGIC score in Black versus White patients.
  • To determine if race should be incorporated into HF risk models.

Main Methods:

  • Analysis of 4046 heart failure patients (1646 Black, 2400 White) from 2007-2015.
  • Tabulation of MAGGIC scores and assessment of discrimination (C-statistic, hazard ratios) and calibration (regression slopes).
  • Cox models were used to analyze MAGGIC score performance stratified by race and in combined analyses.

Main Results:

  • MAGGIC score demonstrated similar discrimination in Black (C-statistic 0.707) and White (C-statistic 0.725) patients.
  • Hazard ratios per MAGGIC point were comparable: 1.12 for Black and 1.13 for White patients.
  • Race was a significant survival correlate (better survival in Black patients), but MAGGIC×race interaction was not significant, and adding race did not improve discrimination.

Conclusions:

  • The MAGGIC score is a validated tool for risk stratifying Black patients with heart failure.
  • The score's performance is comparable between Black and White heart failure populations.
  • Current data support the use of the MAGGIC score without race modification for risk assessment in diverse HF patients.
Abstract

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
790
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.0K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
729
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
278
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
825
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
227